Revvity CP 55940, -, 25uCi (925kBq)

25 µCi quantity of CP 55940, [Side Chain-2,3,4-³H(N)]-, is available for your research.

CP 55,940 is a synthetic cannabinoid that mimics the effects of naturally occuring tetrahydrocannabinol (THC). It acts as a full agonist at cannabinoid receptors type 1 and 2. These GPCRs are potential drug targets for a variety of diseases, including epilepsy, cancer, obesity, and osteoporosis.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET1051:

1. Chiang, Y.-C. and Chen, J.-C. (2007), The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry, 103: 2505–2517.
2. Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, et Al. (2013), The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology, 38: 2373–2384.